Trial · NCT03816891
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Period | STARTED | Phase 2a - Vixarelimab 360 mg SC QW | 24 | |
| Double-Blind Period | STARTED | Phase 2a - Placebo SC QW | 26 | |
| Double-Blind Period | STARTED | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 47 | |
| Double-Blind Period | STARTED | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 47 | |
| Double-Blind Period | STARTED | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 47 | |
| Double-Blind Period | STARTED | Phase 2b - Placebo SC, Q4W (DBL), Then Vixarelimab (OLE) | 49 | |
| Double-Blind Period | Randomized and Treated | Phase 2a - Vixarelimab 360 mg SC QW | 23 | |
| Double-Blind Period | Randomized and Treated | Phase 2a - Placebo SC QW | 26 | |
| Double-Blind Period | Randomized and Treated | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 47 | |
| Double-Blind Period | Randomized and Treated | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 47 | |
| Double-Blind Period | Randomized and Treated | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 47 | |
| Double-Blind Period | Randomized and Treated | Phase 2b - Placebo SC, Q4W (DBL), Then Vixarelimab (OLE) | 48 | |
| Double-Blind Period | Completed Treatment | Phase 2a - Vixarelimab 360 mg SC QW | 23 | |
| Double-Blind Period | Completed Treatment | Phase 2a - Placebo SC QW | 23 | |
| Double-Blind Period | Completed Treatment | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 45 | |
| Double-Blind Period | Completed Treatment | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 44 | |
| Double-Blind Period | Completed Treatment | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 47 | |
| Double-Blind Period | Completed Treatment | Phase 2b - Placebo SC, Q4W (DBL), Then Vixarelimab (OLE) | 47 | |
| Double-Blind Period | COMPLETED | Phase 2a - Vixarelimab 360 mg SC QW | 20 | |
| Double-Blind Period | COMPLETED | Phase 2a - Placebo SC QW | 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03816891/flow